Appeals court nixes GSK’s petition for new trial in Vectura patent spat

The Federal Circuit Court has rejected Glaxo Smith Kline’s (NYSE:GSK) petition for a new trial in a patent case brought by British inhaler company Vectura.

The circuit court upheld a May 2019 jury verdict in U.S. District Court for the District of Delaware, awarding Ventura $89.7 million damages for the period from August 2016 through December 2018 for an infringement on Vectura’s U.S. patent 8303991 by sales of three of GSK’s Ellipta inhalers. The jury found that Vectura had proven that GlaxoSmithKline had infringed claim 3 of patent ‘991.

Get the full story on our sister site, Drug Delivery Business News.